KR20100136710A - Natural antibiotics based on natural products and its composition and function - Google Patents
Natural antibiotics based on natural products and its composition and function Download PDFInfo
- Publication number
- KR20100136710A KR20100136710A KR1020090054944A KR20090054944A KR20100136710A KR 20100136710 A KR20100136710 A KR 20100136710A KR 1020090054944 A KR1020090054944 A KR 1020090054944A KR 20090054944 A KR20090054944 A KR 20090054944A KR 20100136710 A KR20100136710 A KR 20100136710A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- weight
- parts
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 239000003242 anti bacterial agent Substances 0.000 title claims description 30
- 229940088710 antibiotic agent Drugs 0.000 title claims description 25
- 229930014626 natural product Natural products 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 91
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 45
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 45
- 241000894006 Bacteria Species 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000001727 in vivo Methods 0.000 claims abstract description 22
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 18
- 241000193163 Clostridioides difficile Species 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract description 12
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 claims abstract description 11
- 241000193468 Clostridium perfringens Species 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 241000411851 herbal medicine Species 0.000 claims description 22
- 206010052428 Wound Diseases 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 241000194017 Streptococcus Species 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 15
- 239000011593 sulfur Substances 0.000 claims description 15
- 241000193403 Clostridium Species 0.000 claims description 11
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 9
- 241000244206 Nematoda Species 0.000 claims description 8
- 241000295644 Staphylococcaceae Species 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 239000012676 herbal extract Substances 0.000 description 31
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000000605 extraction Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 235000013372 meat Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 244000299790 Rheum rhabarbarum Species 0.000 description 7
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000321 herbal drug Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 244000265736 Nelumbo pentapetala Species 0.000 description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 244000247747 Coptis groenlandica Species 0.000 description 4
- 235000002991 Coptis groenlandica Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 231100000249 enterotoxic Toxicity 0.000 description 4
- 230000002242 enterotoxic effect Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000001497 healthy food Nutrition 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 229940072172 tetracycline antibiotic Drugs 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- -1 Palmitine Chemical compound 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010014665 endocarditis Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 206010028320 muscle necrosis Diseases 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 241000269908 Platichthys flesus Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940124600 folk medicine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000074750 Systenocentrus japonicus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 생약제 혼합 추출물을 유효성분으로 포함하는 천연 항생제에 관한 것이다.The present invention relates to a natural antibiotic comprising the herbal extract as an active ingredient.
생활 수준의 향상과 더불어 식용육(食用肉)의 수요가 크게 늘어나고 있으며, 그에 따라 공급도 늘어나고 있다. 그러나 웰빙시대에 맞추어 가족의 건강에 모두가 심혈을 기울이면서, 육류의 질이 문제가 될 것이다. 특히, 항생제의 남용에 따른 문제는 심각하며 이러한 합성항생제는 사람의 생체에 들어와 세균에 대한 내성을 증가시키는 큰 원인이 되고 있다. 또한, 수출용 해산 어나 육류는 항생제의 남용 때문에 그 공급선이 안정되지 못하여 생산자인 농민이나 어민에게 큰 피해가 돌아가고 있다. 또한, 생산단가를 낮추기 위하여 단위 면적당 동물의 마리수가 너무 많아 생존을 위한 스트레스가 증가하고, 배설물 등에 의하여 병원 미생물에 항상 노출되어 있으며 다양한 질병의 감염에 노출되어 있다. 이러한 질병을 예방하거나 치료하기 위하여 각종 화학요법제가 널리 사용되고 있으며, 이 때에 약제를 적정하게 선정하지 못하였거나, 상용하거나 또는 장기간 투여하므로써 치료 효과가 없이 질병을 악화시키고 있다. 아울러, 세균 자체가 약제에 대한 내성이 증가하여, 치료제의 농도를 날로 높게 사용해야하고, 여러 종류의 약제를 병행하여 사용하게 되므로 경우에 따라서는 새롭게 사용한 약제에 의하여서도 뚜렷한 치료효과를 보지 못하고 있는 실정이다.Along with the improvement of living standards, the demand for edible meat is greatly increasing, and accordingly, the supply is also increasing. However, the quality of meat will be a problem as everyone pays attention to the health of their families in the age of well-being. In particular, the problem caused by the abuse of antibiotics is serious and these synthetic antibiotics are a major cause of increasing the resistance to bacteria entering the human body. In addition, marine fish and meat for export are not stable because of the abuse of antibiotics, causing serious damage to farmers and fishermen who are producers. In addition, in order to lower the production cost, the number of animals per unit area is too large, the stress for survival increases, and is always exposed to the pathogenic microorganisms by feces and the like and are exposed to the infection of various diseases. In order to prevent or treat such diseases, various chemotherapeutic agents are widely used. At this time, a drug is not properly selected, commercially available or long-term administration is exacerbating the disease without a therapeutic effect. In addition, the bacteria themselves have increased resistance to the drug, the concentration of the therapeutic agent must be used day by day, and several types of drugs are used in parallel, so in some cases, the newly used drugs do not show a clear therapeutic effect. to be.
최근에는 질병에 대한 식용동물의 자체방어능력을 향상시키기 위한 사료 및 사료첨가제의 개발, 면역증강제의 개발에 관한 연구를 진행하고 있다. 약제 사용을 규제하기에 충분할 정도로 이들을 실용화 및 보편화하기 위해서는 많은 연구와 시간이 필요할 것으로 보인다. 더구나 최근에는 육류의 조직에 항생물질의 잔류로 소비자의 불신이 증가하고 있고, 환경호르몬의 문제와 더불어 예민하게 떠오르고 있다. 그리고 먹이 연쇄사슬에 따른 항생물질의 축적은 생체에는 무해하더라도 직접적인 항생물질의 투입은 모든 세균들의 내성을 갖게 하며, 이러한 내성이 강한 세균들이 생체 내에 투여되었을 때는 최근의 수퍼박테리아(superbacteria)와 같은 어떠한 강력한 약제로서도 제어되지 않는 균체들이 생겨나 인류의 건강을 위협하게 될 수도 있을 것이다. 이와 같이 식용육의 질병 치료를 위하여 과량의 항생제 투여는 식품으로서의 안정성을 위협할 수 있고, 이는 곧 상품저하를 가져오므로 축산 가에 큰 경제적 손실을 초래할 수밖에 없을 것으로 보인다. 그러므로 사용한 치료약이 육류 내에 잔존하더라도, 이를 섭취한 사람에게 피해가 없고 또한 생태계로 노출되었을 때 자연 분해가 빠르고 쉽게 될 수 있어서, 항생제에 의한 2차적인 문 제를 일으키지 않는 항생제의 개발이 필요하다. 게다가, 동물용 의약품 중 항생제와 항균제를 배합사료에 혼합하는 것은 2011년까지만 허용되고, 오는 2012년부터 전면 금지되며, 농림부는 안전축산물 생산을 위해 배합사료 내 항생·항균제 혼합을 점차 줄이기로 하고, 현행 25종의 항생·항균제 중 테트라싸이클린계 항생제 2종과 인수 공용 항생제 5종 등 7종을 오는 2009년부터 배합사료에 첨가할 수 없도록 했다. 해외에서도 세계보건기구(WHO)가 가축사료용 항생제 사용의 위험을 경고하고, 유럽연합(EU)이 치료목적 외에는 항생제를 투여하지 못하도록 규제하고 있다. 미국 식품의약국(FDA)은 새로 나온 항생제에 한해 치료목적 외에 사용금지 조치를 내렸다. 유럽 가축위생 연맹의 연구 결과에 따르면, 1999년에 농장의 가축들은 EU에서 승인한 전체 항생제의 35%인 4천7백 톤을 소비했지만, 인간은 65%인 8천5백 톤을 소비하였다. 가축이 소비한 항생제 중 3천9백 톤(전체 사용량의 29%)이 가축의 질병치료에 사용되었지만, 사료를 통해 성장촉진제로 사용된 항생제는 786톤(6%)이라고 보고하였다.Recently, research on the development of feed and feed additives and the development of immunostimulants to improve the self-defense ability of food animals against diseases. Much research and time will be needed to make them practical and universal enough to regulate drug use. Moreover, in recent years, distrust of consumers has increased due to the presence of antibiotics in meat tissues, and environmental hormones are emerging with sensitivity. And although the accumulation of antibiotics along the food chain is harmless to living organisms, the direct injection of antibiotics makes all bacteria resistant, and when these resistant bacteria are administered in vivo, there is no evidence of a recent superbacteria, such as superbacteria. Uncontrollable cells, even as powerful drugs, may develop and threaten human health. As such, the administration of an excessive amount of antibiotics for the treatment of edible meat diseases may threaten the stability of foods, which may lead to a decrease in commodities, which inevitably leads to large economic losses in livestock prices. Therefore, even if the used therapeutic agent remains in meat, it is necessary to develop an antibiotic that does not cause harm to the person who consumes it and can be quickly and easily decomposed when exposed to the ecosystem, and thus does not cause secondary problems caused by antibiotics. In addition, the mixing of antibiotics and antimicrobials in veterinary medicines is permitted until 2011, and will be banned from 2012, and the Ministry of Agriculture and Forestry will gradually reduce the mix of antibiotics and antimicrobials in formulated feeds to produce safe livestock products. Of the 25 antibiotics and antimicrobials currently available, seven such as tetracycline antibiotics and five antibiotics are not allowed to be added to blended feeds from 2009. Overseas, the World Health Organization (WHO) warns of the dangers of using antibiotics for livestock feed and regulates the EU from administering antibiotics outside of therapeutic purposes. The US Food and Drug Administration (FDA) has banned the use of new antibiotics in addition to therapeutic purposes. In 1999, farm livestock consumed 4,700 tons, 35% of all EU-approved antibiotics, but humans consumed 8,500 tons, 65%. Of the antibiotics consumed by cattle, 3,900 tonnes (29% of total use) were used to treat livestock disease, but 786 tonnes (6%) of antibiotics used as growth promoters in feed were reported.
이러한 시점에서, 식물추출물에 대한 천연항생제의 개발은 시의 적절하며, 많은 천연식물 추출물 중에는 상당한 정도의 항균성 물질이 존재하고 있으므로, 이들을 식품의 부패방지를 위하여 적용하고자 하는 많은 연구가 진행되고 있다. 따라서 현재에 내성을 갖지 않는 천연산물로부터 합성 항생제를 대용할 수 있는 천연항생제는 축산농가에 필수적인 사항이 되어 가고 있어, 상기 천연항생제는 아주 시급하게 개발되어야 할 것으로 판단된다.At this point, the development of natural antibiotics for plant extracts is timely, and since a considerable amount of antimicrobial substances are present in many natural plant extracts, many studies are being conducted to apply them to food corruption. Therefore, natural antibiotics, which can substitute synthetic antibiotics from natural products that are not resistant to the present, are becoming essential for livestock farms, and thus, the natural antibiotics should be developed very urgently.
스트렙토코커스 속(Streptococcus; S. pyogenes , S. zooepidemicus)은 혈액 의 적혈구를 파괴시켜 수막염, 폐렴, 심장내막염, 근육괴사 등을 일으키는 병원성 균주이며, 사람, 소 말, 닭, 사슴 등에 감염을 일으켜 사망에 이르게 하는 세균성 질병의 원인균이다. 스타필로코시 속(Staphylococci; S. aureus , S. epidermidis)은 독소를 분비하여 사람 및 동물에 다양한 질병을 일으키고, 요리과정 중에 가열에 의해 죽기는 하나 내독소(endotoxin)는 열에 강하여 식중독을 일으키며, 농양, 창상 감염 등의 피부질환, 골관절염, 폐렴, 패혈증, 독소쇼크 증후군을 일으키는, 인후점막에 상재하는 병원성 균주이다. 클로스트리디움 속(Clostridium; C. difficile , C. perfringens)은 독소를 분비하여 여러 가지의 장질환, 치매, 장암 등을 일으킨다.Streptococcus ( S. pyogenes , S. zooepidemicus ) is a pathogenic strain that destroys blood red blood cells, causing meningitis, pneumonia, endocarditis, and muscle necrosis. It is the causative agent of bacterial diseases that leads to. Staphylococci ( S. aureus , S. epidermidis ) secrete toxins and cause various diseases in humans and animals, while they die by heating during cooking, but endotoxins are heat-resistant and cause food poisoning. It is a pathogenic strain located on the throat mucosa causing skin diseases such as abscesses and wound infections, osteoarthritis, pneumonia, sepsis, and toxin shock syndrome. Clostridium ( C. difficile , C. perfringens ) secretes toxins and causes a variety of bowel diseases, dementia and bowel cancer.
황련(Coptis japonica Makino)은 매자나무과(Berberidaceae) 식물로 깽깽이풀이라고 불리며, 가을에 캐서 햇볕에 말려서 약재로 사용한다. 성분으로는 베르베린(Berberine), 콥티신(Coptisinne), 에피베르베린(Epiberberine) 등이 있으며, 한방과 민간에서는 항균, 항염, 위장병, 충혈, 눈병 등의 작용에 사용하는 약재이고 한방에서는 황련해독탕(黃連解毒湯)의 처방으로 해독 및 소염에 사용하고 있다.Cactis japonica Makino is a Berberidaceae plant and is used as a medicinal herb in the fall as it is sunk and dried in the sun. Ingredients include berberine, coptisine, epiberberine, etc.In herbal medicine and folk medicine, it is used for antibacterial, anti-inflammatory, gastrointestinal disease, hyperemia, eye disease, etc.黄連 解毒 湯) is prescribed for detoxification and anti-inflammatory.
오미자(Schizandra chinensis RUPRECHT)는 목련과(Magnoliaceae) 식물로 6 ∼ 7월에 꽃이 피어 열매는 9 ∼10월에 성숙하여 심홍색을 띈다. 오미자는 예로부터 한방에서 전신쇠약, 정신 육체적 피로, 기관지염, 기관지천식, 신경쇠약, 저혈압, 심장기능저하, 영양실조궤양과 상처의 치료 및 시력을 증진시키는데 이용되며, 차 또는 하절기의 화채재료 및 그 색소를 이용한 녹말다식과 오미자주로 가공, 이용되고 있다. 오미자의 항균효과도 보고된바 있다(대한민국 등록특허 제10- 0854567호). Schizandra chinensis RUPRECHT) is a Magnoliaceae plant that blooms in June-July and ripens in September-October and becomes magenta. Schisandra chinensis has been used in traditional medicine to improve systemic weakness, mental and physical fatigue, bronchitis, bronchial asthma, nervous breakdown, hypotension, cardiac dysfunction, malnutrition ulcers and wounds, and to improve visual acuity in tea or summer. It is processed and used mainly in starch foods and Schisandra chinensis using pigments. The antimicrobial effect of Schisandra chinensis has also been reported (Korean Patent No. 10-0854567).
황백(Phellodendron amurense Ruprecht)은 운향과(Rutaceae)의 식물로 황경피나무, 황벽나무라고 불리며, 여름철에 껍질을 벗겨 햇볕에 말려 약재로 사용한다. 황백의 성분으로는 베르베린(Berberine), 팔미틴(Palmitine), 마그로프롤린(Magnoflorine), 구아니딘(Guanidine), 펠로덴드린(Phellodendrine), 야테오리진(Jateorrhizine), 오바쿠논(Obakunone), 칸디신(Candicine) 등이 있으며, 민간 과 한방에서는 항균, 항염, 수렴, 염증성 질병에 이용한 약재이다.Phellodendron amurense Ruprecht ( Phellodendron amurense Ruprecht) is a plant of the Rutaceae, called Rhubarb and Rhubarb , peeled in the summer and dried in the sun for use as a medicinal herb. The components of the white and yellow are Berberine, Palmitine, Magnoflorine, Guanidine, Guellodine, Phellodendrine, Jateorrhizine, Obakunone and Candicein Candicine), and is used in folk medicine and herbal medicine for antibacterial, anti-inflammatory, astringent, and inflammatory diseases.
천문동(天門冬)은 연한 순을 식용하며 뿌리를 진해·이뇨·강장제로 사용한다. 천문동은 맛이 달고 쓰며 성질이 차고 폐경, 신경에 작용하여 페, 신의 음을 보하고 열을 내리며 기침을 멈추게 한다고 하며 약리실험에서는 성분이 아스파라긴이 가래삭이 작용 기침멎이 작용, 항암작용, 오줌내기 작용을 한다. 주요 성분으로는 사포닌(saponin), 플라보노이드(flavonoid), 아스파라긴(asparagine) 등을 함유하고 있다[천문동 자생지 환경 및 생육의 특성, 한약작지, 11(3) 212~215,(2003)]. 또한, 천문동에서 추출된 성분은 콩나물 재배시 항균작용을 하고(대한민국 등록특허 제 10-0415759호), 생체내 유해세균에 대해 항균작용을 하는 것고(대한민국 공개특허 제 10-2003-0068748호)으로 알려져 있다.Cheonmun-dong (天 을) edible light edible roots are used as Jinhae, diuretic, tonic. Astronomical dong is sweet and bitter, has a strong temper, and works on menopause and nerves to stop the coughing, soaking down the fever and stop coughing.In pharmacological experiments, the ingredient is asparagine, sputum, coughing, anticancer, urinating Bet. Its main components include saponin, flavonoids, and asparagine (Astronomical and Environmental Characteristics of Astronomical Dongs, Herbal Medicines, 11 (3) 212 ~ 215, (2003)). In addition, the components extracted from cheonmun-dong has an antimicrobial effect when cultivating bean sprouts (Korean Patent No. 10-0415759), and antimicrobial activity against harmful bacteria in vivo (Korean Patent No. 10-2003-0068748) Known.
상기 황련, 황백, 오미자 및 천문동 등의 각각은 항균 효과가 알려져 있으나, 이들로 구성된 혼합 생약제가 항균작용을 하는지는 보고된 바 없다.The antibacterial effect of each of the sulfur, sulfur, Schizandra chinensis and astronomical dong is known, but it has not been reported whether the mixed herbal medicine composed of these antibacterial action.
이에, 본 발명자들은 상기 황련, 황백, 오미자 및 천문동 추출물로 이루어진 군에서 선택된 2종 이상이 함유된 생약 추출 혼합물이 스트렙토코커스 속, 스타필 로코시 속 및 클로스트리디움 속에 대해 항균효과를 나타냄으로써, 생약성분의 천연항생제로 유용하게 사용될 수 있음을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors have shown that the herbal extract mixture containing two or more selected from the group consisting of the extracts of Hwang, Hwangbaek, Schisandra chinensis and Astronomical dong exhibits an antimicrobial effect against the genus Streptococcus, Staphylococcus and Clostridium, The present invention was completed by confirming that it can be usefully used as a natural antibiotic of herbal ingredients.
본 발명의 목적은 황련, 황백, 오미자 및 천문동 추출물로 이루어진 군에서 선택된 2종 이상이 함유된 생약제 혼합 추출물을 유효성분으로 함유하는 생체내, 장내 또는 상처부위의 유해세균 성장억제용 조성물을 제공하는 것이다.SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for inhibiting growth of harmful bacteria in vivo, intestines or wounds, which contains a mixture of herbal medicines containing two or more selected from the group consisting of rhubarb, baekbaek, schisandra chinensis and astronomical extract as an active ingredient. will be.
본 발명의 다른 목적은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 식물마름병 치료용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for treating plant blight comprising the herbal extract as an active ingredient.
본 발명의 다른 목적은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 생체내 유해세균 성장억제용 건강식품을 제공하는 것이다.Another object of the present invention is to provide a healthy food for inhibiting growth of harmful bacteria in vivo, containing the herbal extract as an active ingredient.
본 발명의 다른 목적은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 항생제를 제공하는 것이다.Another object of the present invention is to provide an antibiotic containing the herbal drug extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 황련, 황백, 오미자 및 천문동 추출물로 이루어진 군에서 선택된 2종 이상이 함유된 생약제 혼합 추출물을 유효성분으로 함유하는 생체내 유해세균 성장억제용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for inhibiting harmful bacterium growth in vivo, containing as an active ingredient a herbal extract mixed extract containing at least two species selected from the group consisting of Hwang lotus, Hwangbaek, Schisandra chinensis and astronomical extract.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 장내 유해세균 성장억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting intestinal harmful bacteria growth containing the herbal extract as an active ingredient.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 상처부위의 유해세균 성장억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting harmful bacterial growth of the wound site containing the herbal extract as an active ingredient.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 식물마름병 치료용 조성물을 제공한다.In addition, the present invention provides a composition for treating plant blight containing the herbal extract as an active ingredient.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 생체내 유해세균 성장억제용 건강식품을 제공한다.In addition, the present invention provides a healthy food for inhibiting growth of harmful bacteria in vivo, containing the herbal extract as an active ingredient.
아울러, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 항생제를 제공한다.In addition, the present invention provides an antibiotic containing the herbal drug extract as an active ingredient.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 황련, 황백, 오미자 및 천문동 추출물로 이루어진 군에서 선택된 2종 이상이 함유된 생약제 혼합 추출물을 유효성분으로 함유하는 생체내 유해세균 성장억제용 조성물을 제공한다.The present invention provides a composition for inhibiting harmful bacterium growth in vivo, containing as an active ingredient a herbal medicine mixed extract containing two or more selected from the group consisting of Huangyan, Hwangbaek, Schisandra chinensis and Astronomical Dong extract.
본 발명의 황련, 황백, 오미자 및 천문동의 추출물은Extracts of the yellow lotus, yellow baek, Schisandra chinensis and Astronomical dong of the present invention
1) 건조한 황련, 황백, 오미자 및 천문동을 각각 분말로 만든 후 추출용매를 각각 가하여 추출하는 단계;1) extracting dried yellow lotus, yellowish white, Schisandra chinensis and astronomical dong into powder, and then adding an extracting solvent to each extract;
2) 단계 1)의 각각의 추출물을 식힌 후 여과하는 단계; 및2) cooling each extract of step 1) and then filtering; And
3) 단계 2)의 각각의 여과액 농축한 후 동결건조하는 단계를 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정되지 않는다.3) is preferably prepared by a manufacturing method comprising the step of concentrating each filtrate of step 2) and lyophilizing, but not always limited thereto.
상기 제조방법에 있어서, 단계 1)의 추출용매는 물, 알코올 또는 이들의 혼 합물인 것이 바람직하고, 상기 알코올로는 C1 내지 C4 저급 알코올을 이용하는 것이 바람직하며, 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하나 이에 한정되지 않는다. 상기 추출용매를 건조된 황련, 황백, 오미자 및 천문동의 분량에 1 내지 1 ~ 10배 첨가하여 추출하는 것이 바람직하며, 3 ~ 5배 첨가하여 추출하는 것이 더욱 바람직하나 이에 한정되지 않는다. 또한, 추출온도는 80 ~ 120℃인 것이 바람직하며, 800℃인 것이 더욱 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 1 ~ 10시간이 바람직하며, 1시간이 더욱 바람직하나 이에 한정하지 않는다. 아울러, 추출 회수는 1 내지 4회인 것이 바람직하나 이에 한정되는 것은 아니다.In the above production method, the extraction solvent of step 1) is preferably water, alcohol or a mixture thereof, it is preferable to use C 1 to C 4 lower alcohol, the lower alcohol is ethanol or methanol It is preferable to use but not limited thereto. The extraction solvent is preferably extracted by adding 1 to 1 to 10 times the amount of dried sulfur lotus, yellowish white, Schizandra and astronomical dong, more preferably 3 to 5 times to extract the extract. In addition, the extraction temperature is preferably 80 ~ 120 ℃, more preferably 800 ℃ but is not limited thereto. In addition, the extraction time is preferably 1 to 10 hours, more preferably 1 hour is not limited thereto. In addition, the extraction number is preferably 1 to 4 times, but is not limited thereto.
상기 제조방법에 있어서, 단계 3)의 농축은 증발농축기를 이용하는 것이 바람직하나 이에 한정되지 않는다. 상기 농축은 20 ~ 60℃에서 농축하는 것이 바람직하고 20 ~ 40℃에서 농축하는 것이 바람직하나 이에 한정되지 않는다. 상기 동결건조는 동결건조기를 이용하는 것이 바람직하고 진동동결건조기를 이용하는 것이 더욱 바람직하나 이에 한정되지 않는다. 상기 동결건조는 -50 ~ -100℃에서 건조하는 것이 바람직하고 -70℃에서 건조하는 것이 바람직하나 이에 한정되지 않는다.In the above production method, the concentration of step 3) is preferably used as an evaporator but not limited thereto. The concentration is preferably concentrated at 20 ~ 60 ℃ and preferably concentrated at 20 ~ 40 ℃ but is not limited thereto. The freeze-drying is preferably using a lyophilizer, more preferably using a vibration freeze dryer, but is not limited thereto. The lyophilization is preferably dried at -50 ~ -100 ℃ and preferably at -70 ℃ is not limited thereto.
본 발명자들은 4가지 생약제 혼합 추출물 즉, 황련, 황백, 오미자 및 천문동을 배합한 생약제 혼합 추출물이 유해 균주의 성장에 미치는 영향을 조사하기 위하여 상기 방법으로 제조한 황련, 황백, 오미자 및 천문동의 추출물을 하기와 같은 중량부로 정량하여 혼합하였다. 본 발명의 생약제 혼합 추출물의 제조를 위한 상 기 추출물의 조성비는 황련 0.1 ~ 6 중량부, 황백 0.1 ~ 6 중량부, 오미자 0.1 ~ 4 중량부, 천문동 0.1 ~ 4 중량부인 것이 바람직하며, 황련 1 ~ 6 중량부, 황백 1 ~ 6 중량부, 오미자 1 ~ 4 중량부, 천문동 1 ~ 4 중량부인 것이 더욱 바람직하며, 황련 3 중량부, 황백 3 중량부, 오미자 2 중량부, 천문동 2 중량부인 것이 가장 바람직하다.The inventors of the present invention to investigate the effect of the four herbal medicines mixed extracts, that is, herbal extracts containing Hwangryeon, Hwangbaek, Schisandra chinensis and Astronomical dong on the growth of harmful strains. Quantitatively mixed by weight as follows. The composition ratio of the extract for the preparation of the herbal medicine mixture extract of the present invention is 0.1 to 6 parts by weight, 0.1 to 6 parts by weight of sulfur white, 0.1 to 4 parts by weight of Schisandra chinensis, 0.1 to 4 parts by weight of cheonmun-dong, More preferably, 6 parts by weight, 1 to 6 parts by weight of sulfur white, 1 to 4 parts by weight of Schizandra chinensis, 1 to 4 parts by weight of astronomical copper, 3 parts by weight of sulfur, 3 parts by weight of sulfur, 2 parts by weight of Schizandra chinensis and 2 parts by weight of Cheonmun-dong desirable.
상기 생체내 유해세균은 장내유해균주인 스트렙토코커스 속의 S. 피오게네스(S. pyogenes), S. 주에피데미쿠스(S. zooepidemicus); 여러 장질환을 일으키는 클로스트리디움 속의 C. 디피클(C. difficile), C. 펄프린젠스(C. perfringens); 및 상처부위에서 다양한 화농성 질환을 일으키는 스타필로코시 속의 S. 아우레우스(S. aureus) 및 S. 에피더미디스(S. epidermidis)를 포함한다.The harmful bacteria in vivo are S. pyogenes of S. pyogenes , S. zooepidemicus in Streptococcus, which is an enterotoxic strain ; Causing many bowel disease Clostridium genus C. D. Pickle (C. difficile), C. Lin pulp Jens (C. perfringens); And S. aureus and S. epidermidis of the genus Staphylococci causing various purulent diseases in the wound.
본 발명에서 실시한 예에서는 장내유해균주인 스트렙토코커스 속의 S. 피오게네스(S. pyogenes) 및 S. 주에피데미쿠스(S. zooepidemicus); 독소를 분비하며 다양한 화농성 질환을 일으키는 스타필로코시 속의 S. 아우레우스(S. aureus), S. 에피더미디스(S. epidermidis); 및, 여러 장질환을 일으키는 클로스트리디움 속의 C. 디피클(C. difficile), C. 펄프린젠스(C. perfringens)를 대상으로, 본 발명의 생약제 혼합 추출물의 상기 유해 균주의 성장에 미치는 영향을 조사하였다. 그 결과, C. 디피클 및 C. 펄프린젠스는 오미자 및 황련에 의하여, S. 아우레우스 및 S. 에피더미디스는 황련에 의하여, S. 피오게네스 및 S. 주에피데미쿠스는 천문동, 황련 및 오미자에 의하여 성장이 억제되는 것을 확인하였다(표 2 참조). 또한, C. 펄프린젠스는 황련+오미자, 황련+천문동 및 황련+황백 추출 혼합물에 의하여, S. 아우레우스는 황련+오미자, 황련+천문동 및 황련+황백 추출 혼합물에 의하여, S. 에피더미디스는 오미자+천문동 및 오미자+황백 추출 혼합물에 의하여, S. 피오게네스는 황련+오미자, 황련+천문동 및 황련+황백 추출 혼합물에 의하여, S. 주에피데미쿠스는 황련+오미자 및 황련+천문동 추출 혼합물에 의하여 성장이 억제되는 것을 확인하였다(표 2 참조). 또한, C. 펄프린젠스는 황련+천문동+황백 추출 혼합물에 의하여, S. 아우레우스는 황련+천문동+황백 추출 혼합물에 의하여, S. 에피더미디스는 오미자+천문동+황백 추출 혼합물에 의하여, S. 피오게네스는 황련+천문동+황백 및 오미자+천문동+황백 추출 혼합물에 의하여, S. 주에피데미쿠스는 황련+천문동+황백 및 오미자+천문동+황백 추출 혼합물에 의하여 성장이 억제되는 것을 확인하였다(표 2 참조). 또한, 황련+천문동+황백+오미자(1:1:1:1) 추출 혼합물에 의하여 상기 6개 균주의 성장이 억제되는 것을 확인하였고(표 2 참조), 특히 황련:황백:오미자:천문동 = 3:3:2:2의 비율로 제조한 혼합 추출물의 효과가 가장 좋은 것으로 나타났다(표 3 및 도 1 참조).Examples in the present invention include S. pyogenes and S. zooepidemicus in Streptococcus, which is an enterotoxic strain ; S. aureus , S. epidermidis in the genus Staphylococci, which secrete toxins and cause various purulent diseases; And, causing a number of bowel disease Clostridium genus C. D. Pickles (C. difficile), C. Lin presence pulp (C. perfringens) in the target, the impact on the growth of the harmful strain of the herbal mixture extract of the present invention Was investigated. As a result, C. difficile and C. pulprinzen by Schisandra chinensis and S. aureus, S. aureus and S. epidermidith by S. japonicus, S. fiogenes and S. z. Epidemius It was confirmed that growth is inhibited by, yellow lotus and Schizandra (see Table 2). In addition, C. pulprinzen was obtained by the mixture of Rum + + Schisandra chinensis, Rum + Rye astronomical and Hwangsi + Hwangbaek, and S. aureus by S. aureus This is done by Schisandra + astronomical dong and Schisandra + yellowish white extract mixture, S. piogenes by S. aureus + Schisandra chinensis, S. aureus + Astronomical dong and Silla + yellow white extract mixture, It was confirmed that growth was inhibited by the extraction mixture (see Table 2). In addition, C. pulprinzen by the Hwangryeon + astronomical dong + Hwangbaek extract mixture, S. aureus by the Hwangryeon + Astronomical dong + Hwangbaek extract mixture, and S. epidermidis by Schisandra + astronomical + Hwangbaek extract mixture, S. pyogenes was found to inhibit growth by H. rye + astronomical dong + hwangbaek and omija + astronomical dong + yellow and white extract mixture, and S. jupitemicus was inhibited by the mixture of rhubarb + astronomical dong + yellow baek and Schisandra + astronomical dong + yellow white extract mixture. (See Table 2). In addition, it was confirmed that growth of the six strains was inhibited by the extract mixture of Hwangyeon + Astronomical + Hwangbaek + Schisandra chinensis (1: 1: 1: 1) (see Table 2). The effect of the mixed extract prepared in a ratio of 3: 3: 2 was found to be the best (see Table 3 and Figure 1).
또한, 본 발명에서 실시한 다른 예에서는 본 발명의 생약제 혼합 추출물에 의해, 장내 유해균주인 클로스트리디움 속의 균주를 뛰어나게 제어하였다(도 2 및 도 3 참조). 또한, 본 발명의 생약제 혼합 추출물은 상처난 래트를 대상으로 한 생체외 실험에서 ① 고름을 생성하여 상처를 곪게 하고, 독소를 분비하여 사람 및 동물에 다양한 질병을 일으키고 식중독을 일으키는 스타필로코시 아우레우스 균주; ② 피부의 상처를 곪게 하고, 농양, 창상, 감염 등의 피부질환, 골관절염, 폐렴, 패혈증, 독소쇼크 증후군을 일으키며, 인후점막에 상재하는 병원성 균주로, 각막궤 양, 양식넙치에 병을 일으키는 스타필로코시 에피더미디스 균주(표피포도상구균); ③ 적혈구를 파괴하여, 수막염, 폐렴, 심장내막염, 근육괴사 등을 일으키는 병원성 균주인 스트렙토코커스 피오게네스 균주; 및, ④ 사람, 소 말, 닭, 사슴 등에 감염을 일으켜 사망에 이르게 하는 세균 스트렙토코커스 주에피데미쿠스 균주의 성장을 억제하여 치유를 훨씬 빠르게 하였다(도 4 내지 도 7 참조).In addition, in another embodiment carried out in the present invention, by controlling the mixed extract of the herbal medicine of the present invention, the strains of the genus Clostridial harmful strains in the intestine were excellently controlled (see Figs. 2 and 3). In addition, the herbal extracts of the present invention, in vitro experiments on wounded rats to produce ① pus to swell the wound, secrete toxins, causing various diseases in humans and animals and staphylococci causing food poisoning Aureus strains; ② wounds ooze of the skin and causes skin diseases, osteoarthritis, pneumonia, sepsis, toxic shock syndrome, such as abscesses, wound infections, as pathogenic strains of merchandise to the throat mucosa, corneal ulcer, star, causing the disease to flounder Phycocosy Epidermidis Strains (epidermal staphylococci); ③ Streptococcus , a pathogenic strain that destroys red blood cells and causes meningitis, pneumonia, endocarditis, and muscle necrosis Piogenes strain; And (4) Bacterial Streptococcus , which causes death by infecting people, cattle, chickens, deer, etc. Jupitemicus Inhibition of the growth of the strain resulted in much faster healing (see FIGS. 4-7).
본 발명의 생체내 유해세균 성장억제용 조성물은 조성물 총 중량에 대하여 상기 생약제 혼합 추출물을 0.1 내지 50 중량%로 포함하는 것이 바람직하나 이에 한정되는 것은 아니다. 본 발명의 생약제 혼합 추출물을 함유하는 조성물은 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.In vivo harmful bacterium growth inhibitory composition of the present invention preferably comprises 0.1 to 50% by weight of the herbal extracts with respect to the total weight of the composition is not limited thereto. The composition containing the herbal drug extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation of the composition.
본 발명의 생체내 유해세균 성장억제용 조성물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.Pharmaceutical dosage forms of the in vivo harmful bacterium growth inhibitory composition of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection. .
본 발명의 조성물은 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환, 과립, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 생약제 혼합 추출물을 함유하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이 트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The compositions of the present invention can be used in the form of powders, granules, tablets, capsules, soft capsules, pills, granules, suspensions, emulsions, syrups, aerosols and the like oral formulations, external preparations, suppositories, and sterile injectable solutions. . Carriers, excipients and diluents that may be included in the composition containing the herbal mixture extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 생약제 혼합 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose, and the like in the herbal extract mixture. (sucrose), lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 액제, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제, 주사제제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, injections. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol,
본 발명의 생체내 유해세균 성장억제용 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 생 약제 혼합 추출물은 1일 0.0001 내지 1000 ㎎/㎏으로, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the in vivo harmful bacterium growth inhibitory composition of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the drug form, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the raw drug mixture extract of the present invention is preferably administered at 0.0001 to 1000 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 생체내 유해세균 성장억제용 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피부 외용, 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다.The harmful bacterium growth inhibitory composition of the present invention may be administered to mammals such as mice, mice, livestock, and humans by various routes. All modes of administration can be expected, for example, oral or parenteral, and may be externally administered, intraperitoneal, rectal, subcutaneous, intravenous, intramuscular or intrathoracic. It is preferable to select the injection method.
본 발명의 생약제 혼합 추출물은 독성 및 부작용은 거의 없으므로 장기간 복용 시에도 안심하고 사용할 수 있는 조성물이다.Herbal medicine mixture extract of the present invention is a composition that can be used with confidence even when taken for a long time because there is little toxicity and side effects.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 장내 유해세균 성장억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting intestinal harmful bacteria growth containing the herbal extract as an active ingredient.
상기 장내 유해세균은 장내유해균주인 스트렙토코커스 속의 S. 피오게네스(S. pyogenes), S. 주에피데미쿠스(S. zooepidemicus); 및, 여러 장질환을 일으키는 클로스트리디움 속의 C. 디피클(C. difficile) 및 C. 펄프린젠스(C. perfringens)를 포함한다.The intestinal harmful bacteria include S. pyogenes and S. zooepidemicus in Streptococcus, which are enterotoxic bacteria ; And, a disease that causes multiple copies of the genus Clostridium C. D. Pickle (C. difficile) and Jens C. Lin pulp (C. perfringens).
생약제 혼합 추출물은 장내 유해균주에 대한 성장 억제 능력이 우수하므로 장내 유해세균 성장억제용 조성물로 유용하게 이용될 수 있다.The herbal extracts can be usefully used as a composition for inhibiting the growth of harmful bacteria in the intestine because it has excellent growth inhibitory ability against intestinal harmful strains.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 상처부위의 유해세균 성장억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting harmful bacterial growth of the wound site containing the herbal extract as an active ingredient.
상기 상처부위의 유해세균은 상처부위에서 다양한 화농성 질환을 일으키는 스타필로코시 속의 S. 아우레우스(S. aureus) 및 S. 에피더미디스(S. epidermidis)를 포함한다.The harmful bacterium of the wound includes S. aureus and S. epidermidis of the genus Staphylococcus which causes various purulent diseases in the wound.
또한, 본 발명의 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피부 외용 또는 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하며, 가장 바람직하게는 피부 외용으로 사용한다.In addition, the composition of the present invention may be administered orally or parenterally, and when parenteral administration is selected by external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method. Preferably, most preferably, it is used for external skin.
생약제 혼합 추출물은 상처부위의 유해균주에 대한 성장 억제 능력이 우수하므로 상처부위의 유해세균 성장억제용 조성물로 유용하게 이용될 수 있다.Since the herbal extract extract is excellent in the ability to inhibit the growth of harmful strains on the wound site can be usefully used as a composition for inhibiting growth of harmful bacteria on the wound site.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 식물마름병 치료용 조성물을 제공한다.In addition, the present invention provides a composition for treating plant blight containing the herbal extract as an active ingredient.
또한, 본 발명에서 실시한 예에서는 본 발명의 생약제 혼합 추출물은 농도의존적으로 선충을 구제하는 것으로 나타났다(도 8 참조). 이에, 본 발명의 생약제 혼합 추출물은 상처부위의 식물 마름병의 원인이 되는 선충에 대한 구제 능력이 우수하므로 식물마름병 치료용 조성물로 유용하게 이용될 수 있다.In addition, in the examples performed in the present invention, the herbal extract of the present invention was found to control nematodes in a concentration-dependent manner (see FIG. 8). Thus, the herbal extracts of the present invention can be usefully used as a composition for treating plant blight because it has an excellent ability to control nematodes that cause plant blight on wounds.
또한, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 생체내 유해세균 성장억제용 건강식품을 제공한다.In addition, the present invention provides a healthy food for inhibiting growth of harmful bacteria in vivo, containing the herbal extract as an active ingredient.
생약제 혼합 추출물은 장내 유해균주 및 상처부위의 유해균주에 대한 성장 억제 능력이 우수하므로 상기 생약제 혼합 추출물을 유효성분으로 함유하는 본 발명의 조성물은 생체내 유해세균 성장억제용 건강식품으로 유용하게 이용될 수 있다.Since the herbal extracts have excellent growth inhibitory ability against harmful strains of intestinal harmful strains and wounds, the composition of the present invention containing the herbal extracts as an active ingredient may be usefully used as a health food for inhibiting harmful bacteria growth in vivo. Can be.
본 발명의 생약제 혼합 추출물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에는 본 발명의 조성물이 원료에 대하여 0.2 내지 20 중량%, 바람직하게는 0.24 내지 10 중량%로 첨가한다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있음은 확실하다.The herbal mixture extract of the present invention may be added to a food as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverages, the composition of the present invention is added at 0.2 to 20% by weight, preferably 0.24 to 10% by weight relative to the raw materials. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. It is certainly.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소세지, 빵, 비스켓, 떡, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강 식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of foods to which the above-mentioned substances may be added include dairy products including drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, Beverages, alcoholic beverages, vitamin complexes, and the like, and include all healthy foods in the conventional sense.
아울러, 본 발명은 상기 생약제 혼합 추출물을 유효성분으로 함유하는 항생제를 제공한다.In addition, the present invention provides an antibiotic containing the herbal drug extract as an active ingredient.
생약제 혼합 추출물은 장내 유해균주 및 상처부위의 유해균주에 대한 성장 억제 능력이 우수하므로 상기 생약제 혼합 추출물을 유효성분으로 함유하는 본 발명의 조성물은 항생제로 유용하게 이용될 수 있다.Since the herbal extracts have excellent growth inhibitory ability against harmful strains of intestinal harmful strains and wounds, the composition of the present invention containing the herbal extracts as an active ingredient may be usefully used as an antibiotic.
본 발명의 생약제 혼합 추출물은 항생제 총 중량부에 대하여 1 내지 100 중량부로 포함할 수 있고, 50 내지 100 중량부로 포함하는 것이 바람직하며, 추가로 약제학적으로 허용되는 1종 이상의 담체에 첨가하여 약제로 제조할 수 있다. 상기 담체로는 식염수, 완충 식염수, 물, 글리세롤 및 에탄올 등이 있으나 이에 한정되지 않으며, 당해 기술 분야에 알려진 적합한 제제(Remingtons's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA)를 모두 사용 가능하다.The herbal medicine extract of the present invention may be included in an amount of 1 to 100 parts by weight, preferably 50 to 100 parts by weight, and further added to one or more pharmaceutically acceptable carriers as a medicament. It can manufacture. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
본 발명의 생약제 혼합 추출물은 부작용이나 내성 없이 생체에 유해한 세균을 제어할 수 있는 천연 항생제를 제공하는 데에 사용될 수 있고, 상처 치유, 선충이 원인이 되는 식물마름병을 치료할 수 있는 제제로 사용될 수 있다.The herbal extracts of the present invention can be used to provide natural antibiotics that can control bacteria harmful to the living body without side effects or resistance, and can be used as an agent for treating plant blight caused by wound healing and nematodes. .
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<실시예 1> 유해 균주 및 배양방법Example 1 Noxious Strains and Culture Methods
<1-1> <1-1> 스트렙토코커스Streptococcus 속의 배양 Cultivation of the genus
펩톤 10.00 g, 고기엑스(Meat extract) 8.00 g, 효모 추출물(Yeast extract) 3.00 g, KH2PO4 2.50 g, K2HPO4 2.50 g, ㎎SO4·7H2O 0.20 g, MnSO4·4 H2O 0.05 g, 글루코오스(Glucose) 5.00 g, 락토오스(Lactose) 5.00 g, 시스테인(Cysteine-HCl·H2O) 0.50 g, 증류수(Distilled water) 1000.00 ㎖, pH 6.8, 멸균후 5% BSA(bovine serum) 첨가한 배지에서, 장내유해균주인 스트렙토코커스 속의 S. 피오게네스(S. pyogenes: KCTC 3096), S. 주에피데미쿠스(S. zooepidemicus: KCTC 3318)를 배양하였다. 250 ㎖의 플라스크에 100 ㎖의 배양액을 넣고 37℃에서 150 rpm으로 교반하면서 배양하였다.Peptone 10.00 g, meat extract (Meat extract) 8.00 g, yeast extract (Yeast extract) 3.00 g,
<1-2> <1-2> 스타필로코시Staphylococci 속의 배양 Cultivation of the genus
KH2PO4 0.5 g, NiCl2·6 H2O 2.0 ㎎, 미량원소(Trace elements) 10.0 ㎖, 황분말(Sulfur, powdered) 30.0 g, 효모 추출물(Difco) 1.0 g, 펩톤(Bacto, Difco) 5.0 g, 레사주린(Resazurin) 1.0 ㎎, 물 1000.0 ㎖로 제조된 배지에서, 독소를 분비하며 다양한 화농성 질환을 일으키는 스타필로코시 속의 S. 아우레우스(S. aureus: KCTC 1928), S. 에피더미디스(S. epidermidis : KCTC 1917)를 배양하였다. 250 ㎖의 플라스크에 100 ㎖의 배양액을 넣고 37℃에서 150 rpm으로 교반하면서 배양하였다.0.5 g of KH 2 PO 4 , 2.0 mg of NiCl 2 · 6 H 2 O, 10.0 ml of trace elements, 30.0 g of sulfur, powdered, 1.0 g of yeast extract (Difco), peptone (Bacto, Difco) 5.0 g, Resazurin 1.0 mg, 1000.0 ml of water, S. aureus ( S. aureus : KCTC 1928), S. epidermis in Staphylococcus, which secrete toxins and cause various purulent diseases Dummy ( S. epidermidis : KCTC 1917) was incubated. 100 ml of the culture solution was added to a 250 ml flask and incubated at 37 ° C. with 150 rpm.
<1-3> 클로스트리디움 속의 배양<1-3> Culture in Clostridium
카제인의 췌장 분해 시약(pancreatic digest of casein) 5.0 g, 프로테아제 펩톤 No3(protease peptone No3) 5.0 g, 쇠고기 엑스(beef extract) 10.0 g, 효모 추출물 3.0 g, 글루코오스 5.0 g, NaCl 5.0 g, 수용성 전분(soluble starch) 1.0 g, 시스테인(cystein) HCl 0.5 g, 아세트산 나트륨(sodium acetate) 3.0 g, 아가(agar) 0.5 g, 정제수(purified water) 1000.0 ㎖로 제조된 pH 6.8로 조절된 RCM(Reinforced Clostridial Medium) 배지에서, 여러 장질환을 일으키는 클로스트리디움 속의 C. 디피클(C. difficile: KCTC 2009), C. 펄프린젠스(C. perfringens: KCTC 3269)를 배양하였다. 250 ㎖의 플라스크에 100 ㎖의 배양액을 넣고 37℃에서 150 rpm으로 교반하면서 배양하였다.5.0 g of pancreatic digest of casein of casein, 5.0 g of protease peptone No3, 10.0 g of beef extract, 3.0 g of yeast extract, 5.0 g of glucose, 5.0 g of soluble starch ( Reinforced Clostridial Medium adjusted to pH 6.8 prepared with 1.0 g of soluble starch, 0.5 g of cysteine HCl, 3.0 g of sodium acetate, 3.0 g of agar, 1000.0 ml of purified water In the medium, C. difficile ( C. difficile : KCTC 2009) and C. perfringens (KCTC 3269) in Clostridium causing various intestinal diseases were cultured. 100 ml of the culture solution was added to a 250 ml flask and incubated at 37 ° C. with 150 rpm.
<< 실시예Example 2> 2> 황련goldthread , 황백, 오, Yellowing, oh 미자Mija 및 And 천문동Astronomical building 추출물의 제조 Preparation of Extract
<2-1> 물 추출물의 제조<2-1> Preparation of Water Extract
황련, 황백, 오미자 및 천문동을 300 g씩을 취하여, 환류 플라스크에 각각 넣고, 물 1,500 ㎖를 가하여 가열하면서 1시간 동안 환류추출하였다. 상기 추출액을 여과한 후 증발농축기를 이용하여 500 ㎖로 농축하였고, 동결건조시켜 분말 30g (수율 10%)을 얻었다.300 g of rhubarb, yellowish white, Schisandra chinensis and astronomical dong were taken, and each was put in a reflux flask, and 1,500 ml of water was added thereto, followed by heating under reflux for 1 hour. The extract was filtered, concentrated to 500 ml using an evaporator, and lyophilized to obtain 30 g of a powder (yield 10%).
상기 황련, 황백, 오미자 및 천문동은 동의보감(東醫寶鑑), 증맥ㆍ방약합편 (證脈·方藥合編), 한방처방의 구성과 적용(韓方處方의 構成과 適用), 도해상용한방처방(圖解 常用漢方處方), 현대한방강좌(現代韓方講座), 현대생약학(現代生藥學) 등의 여러 고서에 수록된 고처방으로부터 수렴, 항염증 작용 및 항균작용을 가지는 것으로 기재된 바를 바탕으로 선택하여 사용하였다.Hwangnyeon, Hwangbaek, Schisandra chinensis and Astronomical dong consist of Dongbobogam, Jeungpang and medicinal herbs, the composition and application of herbal remedies, and prescription Chinese medicine. It was selected based on what is described as having astringent, anti-inflammatory and antimicrobial activity from ancient prescriptions in various books such as 圖 用 漢 方 處方, modern herbal lecture, and modern biopharmaceutical. Used.
<2-2> 에탄올 추출물의 제조<2-2> Preparation of Ethanol Extract
추출용매로 물 대신 에탄올을 사용한 것을 제외하고, 상기 실시예 <1-1>의 추출방법과 동일하게 추출하여 분말(수율 10%)을 얻었다.Except for using ethanol instead of water as the extraction solvent was extracted in the same manner as the extraction method of Example <1-1> to obtain a powder (yield 10%).
<2-3> 메탄올 추출물의 제조<2-3> Preparation of Methanol Extract
추출용매로 물 대신 메탄올을 사용한 것을 제외하고, 상기 실시예 <1-1>의 추출방법과 동일하게 추출하여 분말(수율 10%)을 얻었다.Except for using methanol instead of water as the extraction solvent, the extraction was carried out in the same manner as in the extraction method of Example <1-1> to obtain a powder (yield 10%).
<< 실시예Example 3> 3> 황련goldthread , 황백, 오, Yellowing, oh 미자Mija 및 천문동의 And astronomical agreement 생약재Herbal medicine 추출 혼합물의 제조 Preparation of Extraction Mixture
<3-1> 두 가지 생약재의 추출 혼합물의 제조<3-1> Preparation of Extract Mixture of Two Herbs
상기 황련, 황백, 오미자 및 천문동 추출물 중 두 가지씩을 1:1로 조합한 혼합액을 제조하였다.To prepare a mixed solution of the two combinations of the extract of Hwangyeon, Hwangbaek, Schisandra chinensis and Cheonmundong 1: 1.
<3-2> 세 가지 생약재의 추출 혼합물의 제조<3-2> Preparation of Extract Mixture of Three Herbal Medicines
상기 황련, 황백, 오미자 및 천문동 추출물 중 세 가지씩을 1:1:1로 조합한 혼합액을 제조하였다.Three mixtures of the extracts of Hwangnyeon, Hwangbaek, Schisandra chinensis and Astronomical dong were prepared 1: 1: 1.
<3-3> 네 가지 생약재의 추출 혼합물의 제조<3-3> Preparation of Extract Mixture of Four Herbs
상기 황련, 황백, 오미자 및 천문동 추출물을 1:1:1:1로 조합한 혼합액을 제 조하였다.To prepare a mixed solution of the combination of the extract of Hwangyeon, Hwangbaek, Schisandra chinensis and Cheonmundong 1: 1: 1: 1.
<3-4> 네 가지 생약재의 최적 비율의 추출 혼합물의 제조<3-4> Preparation of Extract Mixture of Optimum Ratio of Four Herbs
상기 황련, 황백, 오미자 및 천문동 추출물을 하기 표 1과 같은 비율로 조합한 혼합액을 제조하였다.The mixture was prepared by combining the extracts of Hwangnyeon, Hwangbaek, Schisandra chinensis and Astronomical dong in the ratio as shown in Table 1 below.
<< 실험예Experimental Example 1> 한 종류의 추출물로부터 각 균주의 제어 1> Control of each strain from one type of extract
실시예 1의 유해 균주에 대한 실시예 2에서 제조한 추출물의 항균효과를 Disk 법으로 확인하였다. 이때, 양성대조군(테트라싸이클린 항생제 50 ㎍/㎖)을 디스크의 가운데에 두었다. 이후, 세균이 자라지 못하는 디스크(Clear zone)의 직경(㎜)을 측정하였다. 직경이 클수록 세균이 잘 자라지 못하는 것으로 나타내었다.The antimicrobial effect of the extract prepared in Example 2 for the harmful strains of Example 1 was confirmed by the Disk method. At this time, a positive control group (50 µg / ml tetracycline antibiotic) was placed in the center of the disk. Then, the diameter (mm) of the disc (Clear zone) in which bacteria do not grow was measured. Larger diameters indicate that bacteria do not grow well.
그 결과, 표 2에 나타난 바와 같이 C. 디피클 및 C. 펄프린젠스는 오미자 및 황련에 의하여,As a result, as shown in Table 2, C. difficle and C. pulpjensen were obtained by Schisandra chinensis and Rhus,
S. 아우레우스 및 S. 에피더미디스는 황련에 의하여,S. aureus and S. epidermidis,
S. 피오게네스 및 S. 주에피데미쿠스는 천문동, 황련 및 오미자에 의하여 성장이 억제되는 것을 확인하였다.S. piogenes and S. zhu epidemius confirmed that growth was inhibited by astronomical dong, rhubarb and schizandra.
<< 실험예Experimental Example 2> 두 종류의 추출 혼합물로부터 각 균주의 제어 2> Control of each strain from two kinds of extraction mixture
실시예 1의 유해 균주에 대한 실시예 3-1에서 제조한 추출 혼합물의 항균효과를 Disk 법으로 확인하였다. 이때, 양성대조군(테트라싸이클린 항생제 50 ㎍/㎖)을 디스크의 가운데에 두었다.The antimicrobial effect of the extract mixture prepared in Example 3-1 for the harmful strains of Example 1 was confirmed by the Disk method. At this time, a positive control group (50 µg / ml tetracycline antibiotic) was placed in the center of the disk.
그 결과, 표 2에 나타난 바와 같이 C. 펄프린젠스는 황련+오미자, 황련+천문동 및 황련+황백 추출 혼합물에 의하여,As a result, as shown in Table 2, C. pulprinzeneun by the extract mixture of rye + + Schisandra chinensis, sulfur + astronomical dong and sulfur + baekbaek,
S. 아우레우스는 황련+오미자,황련+천문동 및 황련+황백 추출 혼합물에 의하여,S. aureus is characterized by the extract of Hunan + Schisandra chinensis, Hunan + Astronomical Dong, and Hunan + Huang White.
S. 에피더미디스는 오미자+천문동 및 오미자+황백 추출 혼합물에 의하여,S. epidermidis was prepared by the Schizandra chinensis + astronomical dong and Schizandra chinensis extract mixture,
S. 피오게네스는 황련+오미자, 황련+천문동 및 황련+황백 추출 혼합물에 의하여,S. piogenes is produced by the extract of Hunan + Schisandra chinensis, Hunan + Astronomical Dong, and Huang + Huang White.
S. 주에피데미쿠스는 황련+오미자 및 황련+천문동 추출 혼합물에 의하여 성장이 억제되는 것을 확인하였다.S. Jupitemicus was confirmed that the growth is inhibited by the extract mixture of Hwangyeon + Schisandra chinensis and Hwangyeon + Astronomical Copper.
<< 실험예Experimental Example 3> 세 종류의 추출 혼합물로부터 각 균주의 제어 3> Control of each strain from three kinds of extraction mixture
실시예 1의 유해 균주에 대한 실시예 3-2에서 제조한 추출 혼합물의 항균효과를 Disk 법으로 확인하였다. 이때, 양성대조군(테트라싸이클린 항생제 50 ㎍/㎖)을 디스크의 가운데에 두었다.The antimicrobial effect of the extract mixture prepared in Example 3-2 for the harmful strains of Example 1 was confirmed by the Disk method. At this time, a positive control group (50 µg / ml tetracycline antibiotic) was placed in the center of the disk.
그 결과, 표 2에 나타난 바와 같이 C. 펄프린젠스는 황련+천문동+황백 추출 혼합물에 의하여,As a result, as shown in Table 2, C. pulprinzeneun by the sulfur mixture + astronomical dong + yellow white extract mixture,
S. 아우레우스는 황련+천문동+황백 추출 혼합물에 의하여,S. aureus is characterized by extracting the mixture of rhubarb + astronomical tract + yellow white,
S. 에피더미디스는 오미자+천문동+황백 추출 혼합물에 의하여,S. epidermidis was prepared by the Schizandra chinensis + Astronomical + Yellow-white extract mixture.
S. 피오게네스는 황련+천문동+황백 및 오미자+천문동+황백 추출 혼합물에 의하여,S. piogenes is prepared by extracting Hwangryeon + Astronomical Dong + Hwangbaek and Schisandra + Astronomical Dong + Yellow White
S. 주에피데미쿠스는 황련+천문동+황백 및 오미자+천문동+황백 추출 혼합물에 의하여 성장이 억제되는 것을 확인하였다.S. Jupitemicus was confirmed that growth is inhibited by the mixture of Hwang Ryun + Astronomical Dong + Yellow White and Schisandra + Astronomical Dong + Yellow White Extract.
<< 실험예Experimental Example 4> 네 종류의 추출 혼합물로부터 각 균주의 제어 4> Control of each strain from four kinds of extraction mixture
실시예 1의 유해 균주에 대한 실시예 3-3에서 제조한 추출 혼합물의 항균효과를 Disk 법으로 확인하였다.The antimicrobial effect of the extract mixture prepared in Example 3-3 for the harmful strains of Example 1 was confirmed by the Disk method.
그 결과, 표 2에 나타난 바와 같이 상기 6개 균주에 대해 황련+천문동+황백+오미자(1:1:1:1) 추출 혼합물에 의하여 성장이 억제되는 것을 확인하였다.As a result, as shown in Table 2, it was confirmed that growth was inhibited by the extract of Hwangryeon + Astronomical + Hwangbaek + Schisandra chinensis (1: 1: 1: 1) for the six strains.
<< 실험예Experimental Example 5> 최적 혼합 비율에 의한 5> By optimum mixing ratio 각 균주의 제어Control of each strain
실시예 1의 유해 균주에 대한 실시예 3-4에서 제조한 추출 혼합물의 항균효과를 Disk 법으로 확인하였다.The antimicrobial effect of the extract mixture prepared in Example 3-4 for the harmful strains of Example 1 was confirmed by the Disk method.
그 결과, 표 3 및 도 1에서 나타난 바와 같이 황련 : 황백 : 오미자: 천문동 = 3:3:2:2의 비율로 제조한 혼합 추출물(B7)의 효과가 가장 좋은 것으로 나타났다.As a result, as shown in Table 3 and Figure 1 it was shown that the best effect of the mixed extract (B7) prepared in the ratio of yellow: yellow white: Schisandra chinensis: astronomical dong = 3: 3: 2: 2 :.
<< 실험예Experimental Example 6> 생약제 혼합 추출물에 의한 6> By herbal extract 생체내In vivo 클로스트리디움Clostridium 속 균주의 제어 Control of genus strains
4 주령의 수컷 또는 암컷 마우스 8마리를 1주일간 순화하고 1주일간 사육하면서 1%의 생약제 혼합 추출물(0.2% -sucrosevh함)을 100 ㎕/200 g(마우스 무게)을 매일 1회 경구 투여하였다. 1주일 후에 배설물을 수득하여 FISH 키트로 전처리한 후, 형광현미경으로 관찰하였다.Eight male or female mice, 4 weeks of age, were purified for 1 week and were bred for 1 week while 100 μl / 200 g (mouse weight) of 1% crude drug mixture extract (0.2% -sucrosevh) was administered orally once daily. After one week, the excreta was obtained and pretreated with a FISH kit, which was then observed with a fluorescence microscope.
그 결과, 도 2(수컷) 및 도 3(암컷)에 나타난 바와 같이 대조군보다 현저히 유해 균주가 줄어들었으며, 본 발명의 생약제 혼합 추출물에 의해, 생체내의 장염, 치매, 장암 등의 원인이 되는 클로스트리디움 속의 균주를 뛰어나게 제어하는 것을 확인하였다.As a result, as shown in Figure 2 (male) and Figure 3 (female) significantly less harmful strains than the control group, by the herbal extract mixed extract of the present invention, a clot tree that causes intestinal inflammation, dementia, intestinal cancer, etc. in vivo It was confirmed that excellent control of the strain in the medium.
<< 실험예Experimental Example 7> 생약제 혼합 추출물에 의한 7> By herbal extract 생체내In vivo 외상에서 유해 균주의 제어 Control of Harmful Strains in Trauma
① 고름을 생성하여 상처를 곪게 하고, 독소를 분비하여 사람 및 동물에 다양한 질병을 일으키고 식중독을 일으키는 스타필로코시 아우레우스 균주;① Staphylococcus that produces pus to break wounds, secretes toxins, causes various diseases in humans and animals, and causes food poisoning Aureus strains;
② 피부의 상처를 곪게 하고, 농양, 창상, 감염 등의 피부질환, 골관절염, 폐렴, 패혈증, 독소쇼크 증후군을 일으키며, 인후점막에 상재하는 병원성 균주로, 각막궤양, 양식넙치에 병을 일으키는 스타필로코시 에피더미디스 균주(표피포도상구균);② wounds ooze of the skin and causes skin diseases, osteoarthritis, pneumonia, sepsis, toxic shock syndrome, such as abscesses, wound infections, as pathogenic strains of merchandise to the throat mucosa, causing illness in corneal ulcers, flounder Staphylococcus Kosi Epidermidis Strains (epidermal staphylococci);
③ 적혈구를 파괴하여, 수막염, 폐렴, 심장내막염, 근육괴사 등을 일으키는 병원성 균주인 스트렙토코커스 피오게네스 균주; 및,③ Streptococcus , a pathogenic strain that destroys red blood cells and causes meningitis, pneumonia, endocarditis, and muscle necrosis Piogenes strain; And,
④ 사람, 소 말, 닭, 사슴 등에 감염을 일으켜 사망에 이르게 하는 세균 스트렙토코커스 주에피데미쿠스 균주④ Bacterial Streptococcus Jupitemicus , which causes humans, cows, chickens, deer, etc. to cause death Strain
를, S.D.계열의 래트(rat)에 상처를 내고, 도포하여 치유되는 과정을 관찰하였다.The wounds of the S.D. series rats were applied and observed for healing.
그 결과, 도 4 내지 도 7에 나타난 바와 같이 본 발명의 생약제 혼합 추출물을 도포한 그룹이 시간의 경과에 따라 훨씬 빠른 치유를 보이고 있어 생약제 혼합 추출물이 스타필로코시 아우레우스 균주를 잘 제어하는 것을 확인하였다.As a result, as shown in Figures 4 to 7, the group to which the herbal drug mixture extract of the present invention is applied shows a much faster healing as time passes, so that the herbal drug extract is well controlled staphylococcus aureus strain. Confirmed.
<< 실험예Experimental Example 8> 생약제 혼합 추출물에 의한 8> by herbal extract 선충의Nematode 구제 salvation
식물 마름병의 원인이 되는 선충을 플레이트에 놓은 후, 0.01%, 0.5% 및 1.0%의 생약제 혼합 추출물을 농도별로 투여하였을 때 선충이 농도의존적으로 구제되는 것을 확인하였다(도 8).After the nematodes, which cause plant blight, were placed on the plate, it was confirmed that the nematodes were controlled in a concentration-dependent manner when 0.01%, 0.5%, and 1.0% of the herbal extracts were administered at different concentrations (FIG. 8).
도 1은 추출 혼합물의 통합처방에 의한 항균 활성을 나타낸 도이다.1 is a view showing the antimicrobial activity by the integrated prescription of the extraction mixture.
도 2는 추출 혼합물의 최적 혼합 비율에 의한 항균 활성을 나타낸 도이다.2 is a diagram showing the antimicrobial activity by the optimum mixing ratio of the extraction mixture.
도 3은 클로스트리디움 속의 균주를 본 발명의 추출 혼합물이 처리된 수컷 쥐의 배설물로부터 채취하여 균의 수를 측정한 도이다.3 is a diagram showing the number of bacteria from strains of Clostridium from the feces of male rats treated with the extract mixture of the present invention.
도 4는 클로스트리디움 속의 균주를 본 발명의 추출 혼합물이 처리된 암컷 쥐의 배설물로부터 채취하여 균의 수를 측정한 도이다.Figure 4 is a diagram measuring the number of bacteria from strains of Clostridium from the feces of female rats treated with the extract mixture of the present invention.
도 5는 스타필로코시 아루레우스 균주로부터 본 발명의 추출 혼합물이 처리된 쥐의 치유되는 과정을 나타낸 도이다.Figure 5 is a diagram showing the healing process of rats treated with the extract mixture of the present invention from the Staphylococcus aureus strain.
도 6은 스타필로코시 에피더미디스 균주로부터 본 발명의 추출 혼합물이 처리된 쥐의 치유되는 과정을 나타낸 도이다.Figure 6 is a diagram showing the process of healing mice treated with the extract mixture of the present invention from the Staphylococcus epidermidis strain.
도 7은 스트렙토코커스 피오게네스 균주로부터 본 발명의 추출 혼합물이 처리된 쥐의 치유되는 과정을 나타낸 도이다.Figure 7 is a diagram showing the healing process of rats treated with the extract mixture of the present invention from Streptococcus piogenes strain.
도 8은 스트렙토코커스 주에피데미쿠스 균주로부터 본 발명의 추출 혼합물이 처리된 쥐의 치유되는 과정을 나타낸 도이다.Figure 8 is a diagram showing the healing process of the rats treated with the extract mixture of the present invention from the Streptococcus main epidemius strain.
도 13은 추출 혼합물로부터 선충에 대한 제어 활성을 나타낸 도이다.Figure 13 shows the control activity against nematodes from the extraction mixture.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090054944A KR101079711B1 (en) | 2009-06-19 | 2009-06-19 | Natural Antibiotics Based on Natural Products and Its Composition and Function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090054944A KR101079711B1 (en) | 2009-06-19 | 2009-06-19 | Natural Antibiotics Based on Natural Products and Its Composition and Function |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100136710A true KR20100136710A (en) | 2010-12-29 |
KR101079711B1 KR101079711B1 (en) | 2011-11-03 |
Family
ID=43510650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090054944A KR101079711B1 (en) | 2009-06-19 | 2009-06-19 | Natural Antibiotics Based on Natural Products and Its Composition and Function |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101079711B1 (en) |
-
2009
- 2009-06-19 KR KR1020090054944A patent/KR101079711B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101079711B1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110125318A (en) | Antibiotic composition comprising plants extract mixture | |
KR100777833B1 (en) | composition comprising an extract of Schizandra chinensis showing antibacterial activity | |
KR102705038B1 (en) | Antimicrobial composition against fish bacterial disease comprising Cudrania tricuspidata Bureau extract or fraction as an active ingredient | |
KR102468406B1 (en) | A ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L. | |
KR102181220B1 (en) | Pharmaceutical composition for anti-cancer containing medicinal gerb extracts | |
KR101851167B1 (en) | Pharmaceutical composition containing extract of Spiraea prunifolia for prevention and treatment of allergic diease | |
KR101710588B1 (en) | A composition comprising the extract of plantago asiatica showing anti-toxoplasma activity | |
KR102157795B1 (en) | A pharmaceutical composition comprising water extract of Lonicerae Flos for preventing or treating of Helicobacter pylori infectious diseases | |
CN107260774A (en) | The purposes of wax-cakes bait Genes For Plant Tolerance pathogenic infection | |
KR100854567B1 (en) | Composition comprising an extract of prunus fructus, schizandrae fructus, coptidis rhizoma showing antibacterial activity | |
WO2004103387A1 (en) | The uses of bamboo leaf total flavones for the preparation of medicaments and health foods for preventing and treating for prostate diseases | |
KR20150047047A (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising water extract containing baicalin from Scutellaria baicalensis through immune modulation | |
KR101444416B1 (en) | Pharmaceutical composition for preventing or treating infectious diseases by pathogenic microorganism comprising extract of Rubus coreanus branch as effective component | |
KR101079711B1 (en) | Natural Antibiotics Based on Natural Products and Its Composition and Function | |
US20240115644A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
KR101865142B1 (en) | Pharmaceutical composition containing combination extract of Spiraea prunifolia, Pyrus pyrifolia and Geum japonicum for prevention and treatment of allergic diease | |
WO2015122728A1 (en) | Anti-tuberculosis composition for treating and preventing tuberculosis comprising melia azedarach l. extract or lobelia chinensis lour extract and fractions thereof | |
KR20070096688A (en) | Antibacterial composition containing the extract of fraxinus rhynchophylla or the compounds isolated therefrom | |
KR20190006285A (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR101803046B1 (en) | Anti-cancer composition comprising alcohol extracts of Selaginella tamariscina as an active ingredient for combinational administration with chemotherapeutics | |
WO2016182158A1 (en) | Composition containing lactuca scariola extract as active ingredient for preventing or treating periodontal disease | |
KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
KR101711397B1 (en) | Pharmaceutical compositions and health functional foods comprising Persicaria fauriei extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
KR101353943B1 (en) | Composition comprising fermented Dioscorea opposita Thunb. for preventing and treating a gastrointestinal disorder | |
KR100406773B1 (en) | Antimicrobial composition containing sea squirt integument extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141007 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151028 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171024 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |